Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Palisade Bio (PALI) over the last 15 years, with Q3 2025 value amounting to $1.2 million.

  • Palisade Bio's Accumulated Expenses fell 1915.18% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 1915.18%. This contributed to the annual value of $1.2 million for FY2024, which is 4921.78% up from last year.
  • According to the latest figures from Q3 2025, Palisade Bio's Accumulated Expenses is $1.2 million, which was down 1915.18% from $2.1 million recorded in Q2 2025.
  • Palisade Bio's Accumulated Expenses' 5-year high stood at $2.1 million during Q2 2025, with a 5-year trough of $274261.0 in Q1 2021.
  • Over the past 5 years, Palisade Bio's median Accumulated Expenses value was $994500.0 (recorded in 2021), while the average stood at $1.1 million.
  • As far as peak fluctuations go, Palisade Bio's Accumulated Expenses surged by 86708.86% in 2021, and later plummeted by 4672.41% in 2023.
  • Palisade Bio's Accumulated Expenses (Quarter) stood at $722000.0 in 2021, then dropped by 20.5% to $574000.0 in 2022, then surged by 44.77% to $831000.0 in 2023, then skyrocketed by 49.22% to $1.2 million in 2024, then decreased by 1.61% to $1.2 million in 2025.
  • Its Accumulated Expenses stands at $1.2 million for Q3 2025, versus $2.1 million for Q2 2025 and $1.9 million for Q1 2025.